High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Summary: Hyperglycemia is a recognized risk factor for bladder cancer (BC). Enfortumab vedotin (EV), the first NECTIN4-targeting antibody-drug conjugate, demonstrates promising clinical efficacy in patients with advanced BC. In this study, we show that EV treatment is less effective in BC patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhuo Xing, Tiejun Yang, Xurui Li, Haozhe Xu, Yulong Hong, Shuai Shao, Tao Li, Liefu Ye, Yuan Li, Xin Jin, Yongbao Wei
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Cell Reports
Subjects:
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S221112472500316X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items